Olmetec and Poor venous access - a phase IV clinical study of FDA data

Summary:

Poor venous access is reported as a side effect among people who take Olmetec (olmesartan medoxomil), especially for people who are male, 50-59 old, also take Actemra, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Poor venous access when taking Olmetec. It is created by eHealthMe based on reports of 7,816 people who have side effects when taking Olmetec from the FDA, and is updated regularly.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.

What is Poor venous access?

Poor venous access is found to be associated with 673 drugs and 479 conditions by eHealthMe. Check the latest studies of Poor venous access.

On Jul, 09, 2026

7,816 people reported to have side effects when taking Olmetec.
Among them, 24 people (0.31%) have Poor venous access.

Among these 24 people:

What is the gender of people who have Poor venous access when taking Olmetec? *

female: 50 %
male: 50 %

What is the age of people who have Poor venous access when taking Olmetec? *

What are other drugs people take besides Olmetec? *

What are other side effects people have besides Poor venous access? *

Lump In The Abdomen (an area of swelling or growth on abdomen): 15 people, 62.50%
Abdominal Pain: 15 people, 62.50%
Diarrhea: 13 people, 54.17%
Pain: 12 people, 50.00%
Back Pain: 10 people, 41.67%
Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 9 people, 37.50%
Gout (uric acid crystals building up in the body): 8 people, 33.33%
Heart Rate Increased: 8 people, 33.33%
Gastroenteritis Viral (inflammation of stomach and intestine caused by virus infection): 8 people, 33.33%
Balance Disorder: 8 people, 33.33%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 10 people, 41.67%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 9 people, 37.50%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 33.33%
Blood Pressure Abnormal: 8 people, 33.33%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 3 people, 12.50%
Oral Cancer (mouth cancer): 2 people, 8.33%
Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 1 person, 4.17%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 4.17%
Enlarged Prostate: 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Olmetec and have Poor venous access?

- Check whether Poor venous access is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Olmetec:

Olmetec (7,904 reports)

Browse all side effects of Olmetec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Poor venous access:

Poor venous access (673 drugs)

Browse all the conditions that are associated with Poor venous access:

Poor venous access (479 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on olmesartan medoxomil (the active ingredients of Olmetec) and Olmetec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.